Yongjiang Li - Search Results

Year	Number of Results
2004	1
2008	2
2009	2
2010	2
2011	1
2012	3
2013	4
2014	5
2015	6
2016	6
2017	13
2018	12
2019	20
2020	12
2021	23
2022	18
2023	15
2024	5

1

Artificial exosomes for translational nanomedicine.

Li YJ, Wu JY, Liu J, Xu W, Qiu X, Huang S, Hu XB, Xiang DX. Li YJ, et al. J Nanobiotechnology. 2021 Aug 12;19(1):242. doi: 10.1186/s12951-021-00986-2. J Nanobiotechnology. 2021. PMID: 34384440 Free PMC article. Review.

2

Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy.

Li Y, Wu J, Qiu X, Dong S, He J, Liu J, Xu W, Huang S, Hu X, Xiang DX. Li Y, et al. Bioact Mater. 2022 Jun 29;20:548-560. doi: 10.1016/j.bioactmat.2022.05.037. eCollection 2023 Feb. Bioact Mater. 2022. PMID: 35846843 Free PMC article.

3

Oral Hydrogel Microbeads-Mediated In Situ Synthesis of Selenoproteins for Regulating Intestinal Immunity and Microbiota.

Ouyang J, Deng B, Zou B, Li Y, Bu Q, Tian Y, Chen M, Chen W, Kong N, Chen T, Tao W. Ouyang J, et al. Among authors: li y. J Am Chem Soc. 2023 Jun 7;145(22):12193-12205. doi: 10.1021/jacs.3c02179. Epub 2023 May 19. J Am Chem Soc. 2023. PMID: 37208802

4

Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity.

Li Y, Chen W, Kang Y, Zhen X, Zhou Z, Liu C, Chen S, Huang X, Liu HJ, Koo S, Kong N, Ji X, Xie T, Tao W. Li Y, et al. Nat Commun. 2023 Nov 1;14(1):6973. doi: 10.1038/s41467-023-42509-7. Nat Commun. 2023. PMID: 37914681 Free PMC article.

5

Chemically Modified Platforms for Better RNA Therapeutics.

Shi Y, Zhen X, Zhang Y, Li Y, Koo S, Saiding Q, Kong N, Liu G, Chen W, Tao W. Shi Y, et al. Among authors: li y. Chem Rev. 2024 Feb 14;124(3):929-1033. doi: 10.1021/acs.chemrev.3c00611. Epub 2024 Jan 29. Chem Rev. 2024. PMID: 38284616 Review.

6

Macrophage-modulating nanomedicine for cancer immunotherapy.

Khan MM, Li Y, Zhou Z, Ni A, Saiding Q, Qin D, Tao W, Chen W. Khan MM, et al. Among authors: li y. Nanoscale. 2024 Apr 18;16(15):7378-7386. doi: 10.1039/d3nr06333j. Nanoscale. 2024. PMID: 38511468 Review.

7

Nonviral delivery systems for antisense oligonucleotide therapeutics.

Huang S, Hao XY, Li YJ, Wu JY, Xiang DX, Luo S. Huang S, et al. Biomater Res. 2022 Sep 30;26(1):49. doi: 10.1186/s40824-022-00292-4. Biomater Res. 2022. PMID: 36180936 Free PMC article. Review.

8

Apoptotic bodies for advanced drug delivery and therapy.

Zhou M, Li YJ, Tang YC, Hao XY, Xu WJ, Xiang DX, Wu JY. Zhou M, et al. J Control Release. 2022 Nov;351:394-406. doi: 10.1016/j.jconrel.2022.09.045. Epub 2022 Sep 27. J Control Release. 2022. PMID: 36167267 Review.

9

Recent progress of macrophage vesicle-based drug delivery systems.

Xu WJ, Cai JX, Li YJ, Wu JY, Xiang D. Xu WJ, et al. Drug Deliv Transl Res. 2022 Oct;12(10):2287-2302. doi: 10.1007/s13346-021-01110-5. Epub 2022 Jan 4. Drug Deliv Transl Res. 2022. PMID: 34984664 Review.

10

Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer.

Li YJ, Wu JY, Wang JM, Xiang DX. Li YJ, et al. J Control Release. 2020 Apr 10;320:105-111. doi: 10.1016/j.jconrel.2020.01.041. Epub 2020 Jan 21. J Control Release. 2020. PMID: 31978441 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

134 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year